Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04258969 | Pedaling at a Low-Moderate Intensity During Chemotherapy Administration | N/A | withdrawn | Feb 6, 2020 | Rush University Medical Center | lack of resources | Other (stated, no rule matched) |
| NCT05397171 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants… | Phase 1 / Phase 2 | terminated | May 31, 2022 | AstraZeneca | This study was terminated early as per protocol Section 4.4, based on overall risk-benefit profile… | Safety / toxicity |
| NCT04517448 | Quality of Life of Patients Over 75 Yars Undergoing Palliative Chemotherapy(EQLVCPAL) | — | terminated | Aug 18, 2020 | Centre Hospitalier de la côte Basque | End of recruitment - Number of required subjects enrolled | Enrollment / accrual |
| NCT05518032 | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal… | Phase 2 | withdrawn | Aug 26, 2022 | Roswell Park Cancer Institute | prioritization of studies | Other (stated, no rule matched) |
| NCT05780736 | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or…(PROSPECT-ESO) | — | terminated | Mar 23, 2023 | Bristol-Myers Squibb | A decision was made to terminate the study due to expected timelines associated with start-up,… | Enrollment / accrual |
| NCT03716596 | SBRT and Anti-programmed Cell Death Protein 1(Anti-PD-1) in Late Stage or Recurrent…(CISPD-2) | Phase 1 | terminated | Oct 23, 2018 | Second Affiliated Hospital, Zhejiang University, School of Medicine | The effect of the regime was not satisfied | Other (stated, no rule matched) |
| NCT04488159 | Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer(iMAGINE) | Phase 3 | withdrawn | Jul 27, 2020 | Johannes Laengle, MD, PhD | Lack of funding. | Funding |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE)… | Phase 2 | terminated | Apr 28, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular… | Phase 2 | terminated | Jun 2, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns | Safety / toxicity |
| NCT02745197 | A Study to See Whether a Nutritional Supplement is Beneficial for Patients With… | Phase 2 | withdrawn | Apr 20, 2016 | University of Alberta | change in concept | Other (stated, no rule matched) |
| NCT03844347 | Well-being and Stress Control After Colorectal Surgery(C-Bien) | N/A | terminated | Feb 18, 2019 | University Hospital, Strasbourg, France | recruitment difficulties | Enrollment / accrual |
| NCT05188586 | New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)(NODMED) | N/A | terminated | Jan 12, 2022 | ClearNote Health | enrollment targets not met | Enrollment / accrual |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive… | Phase 2 | withdrawn | May 2, 2022 | Academic and Community Cancer Research United | no sites were regulatory ready and the SC took the study to a different group. | Other (stated, no rule matched) |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With… | Phase 2 | withdrawn | Sep 22, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT03148093 | The CHOICE Registry | — | terminated | May 10, 2017 | Taiho Oncology, Inc. | Competing clinical trials and slower than expected patient enrollment | Enrollment / accrual |
| NCT04752358 | ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric… | Phase 2 | terminated | Feb 12, 2021 | Adaptimmune | Study was terminated due to difficulty recruiting subjects and lack of efficacy | Efficacy / futility |
| NCT03594448 | Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients | — | terminated | Jul 20, 2018 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as…(SBRTvsTACE) | Phase 3 | terminated | May 22, 2019 | Lahey Clinic | This study was closed early due to lack of enrollments and insufficient funding. | Enrollment / accrual |
| NCT03586869 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | Phase 1 / Phase 2 | terminated | Jul 16, 2018 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally… | Phase 1 / Phase 2 | withdrawn | Aug 23, 2023 | M.D. Anderson Cancer Center | 0 participants registered | Other (stated, no rule matched) |
| NCT06054308 | Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable…(CART) | N/A | withdrawn | Sep 26, 2023 | Chinese University of Hong Kong | Unable to obtain Clinical Trial Certificate due to tech Unable to obtain Clinical Trial Certificate… | Other (stated, no rule matched) |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT05223673 | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus…(COLSTAR) | Phase 3 | terminated | Feb 4, 2022 | Institut de Recherches Internationales Servier | Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not… | Sponsor / business decision |
| NCT06216561 | Intraperitoneal LSTA1 in CRS-HIPEC | Phase 1 | withdrawn | Jan 22, 2024 | University of California, San Diego | closed early due to low (0) accrual | Enrollment / accrual |
| NCT05450393 | Data Collection of PillCamTM SB3 Capsule Endoscopy and Device-Assisted Enteroscopy… | — | withdrawn | Jul 8, 2022 | Medtronic - MITG | Study was cancelled by sponsor due to priority realignment | Other (stated, no rule matched) |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | Phase 2 | withdrawn | Oct 31, 2023 | Case Comprehensive Cancer Center | PI left the institution | Investigator |
| NCT06518538 | Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With… | Phase 2 | withdrawn | Jul 24, 2024 | Cornerstone Pharmaceuticals | due to study redesign | Other (stated, no rule matched) |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer… | Phase 2 | terminated | Jan 16, 2024 | LianBio LLC | Business Reason | Sponsor / business decision |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT03866239 | A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in… | Phase 1 | terminated | Mar 7, 2019 | Hoffmann-La Roche | The Sponsor terminated the study because development of cibisatamab has been discontinued. | Other (stated, no rule matched) |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | Phase 1 | terminated | Apr 29, 2022 | jianming xu | achieve the proof of concept | Other (stated, no rule matched) |
| NCT05672342 | Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy… | Early Phase 1 | withdrawn | Jan 5, 2023 | City of Hope Medical Center | withdrawn | Other (stated, no rule matched) |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | Phase 1 | withdrawn | Mar 29, 2024 | Abramson Cancer Center at Penn Medicine | Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280)… | Enrollment / accrual |
| NCT02798003 | Food Reward in Cachexia Induced by Acute or Chronic Disease | — | terminated | Jun 14, 2016 | Maastricht University Medical Center | Not feasible to include the needed patients | Other (stated, no rule matched) |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803… | Phase 1 / Phase 2 | terminated | Apr 25, 2017 | NantCell, Inc. | The study was terminated before any dose escalation occurred in order to pursue other studies… | Other (stated, no rule matched) |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B… | Phase 1 / Phase 2 | terminated | Aug 4, 2020 | University of Michigan Rogel Cancer Center | loss of funding | Funding |
| NCT05898828 | Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With… | Phase 1 / Phase 2 | withdrawn | Jun 12, 2023 | National Cancer Institute (NCI) | No enrollment | Enrollment / accrual |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable… | Phase 2 / Phase 3 | terminated | Jun 7, 2005 | Astex Pharmaceuticals, Inc. | not stated | Not stated |
| NCT04231526 | Pembrolizumab in Early Stage Colon Cancer | Phase 2 | withdrawn | Jan 18, 2020 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT04408599 | A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 29, 2020 | NextCure, Inc. | Upon completion of the Phase 1 portion of the NC410 monotherapy trial, NextCure focused efforts on… | Other (stated, no rule matched) |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in… | Phase 1 / Phase 2 | terminated | Dec 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of… | Sponsor / business decision |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
| NCT05039944 | SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of… | Phase 2 | terminated | Sep 10, 2021 | Sichuan Baili Pharmaceutical Co., Ltd. | Company research strategy adjustment | Sponsor / business decision |
| NCT03956056 | Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical… | Phase 1 | terminated | May 20, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT01855607 | Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy | Phase 2 | terminated | May 16, 2013 | Columbia University | Poor enrollment | Enrollment / accrual |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular… | Phase 1 / Phase 2 | terminated | Dec 10, 2014 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Sponsor decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 1, 2024source: clinicaltrials